Windtree Therapeutics, Inc. (NASDAQ:WINT – Get Rating) was the target of a large drop in short interest during the month of December. As of December 30th, there was short interest totalling 905,900 shares, a drop of 28.7% from the December 15th total of 1,270,000 shares. Based on an average daily volume of 448,000 shares, the short-interest ratio is currently 2.0 days.
Wall Street Analysts Forecast Growth
Separately, Oppenheimer cut their price target on Windtree Therapeutics to $1.00 in a report on Thursday, November 17th.
Windtree Therapeutics Trading Down 25.7 %
Shares of NASDAQ WINT opened at $0.16 on Friday. The company has a market cap of $6.25 million, a price-to-earnings ratio of -0.11 and a beta of 0.25. Windtree Therapeutics has a 12-month low of $0.14 and a 12-month high of $1.44. The company has a current ratio of 2.54, a quick ratio of 2.54 and a debt-to-equity ratio of 0.86. The stock’s 50 day simple moving average is $0.17 and its 200 day simple moving average is $0.17.
Institutional Trading of Windtree Therapeutics
Several large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its position in Windtree Therapeutics by 54.1% in the 2nd quarter. Renaissance Technologies LLC now owns 361,395 shares of the company’s stock valued at $151,000 after acquiring an additional 126,949 shares during the period. PVG Asset Management Corp acquired a new stake in Windtree Therapeutics in the 3rd quarter valued at approximately $56,000. Envestnet Asset Management Inc. increased its position in Windtree Therapeutics by 894.7% in the 3rd quarter. Envestnet Asset Management Inc. now owns 107,302 shares of the company’s stock valued at $32,000 after acquiring an additional 96,515 shares during the period. Virtu Financial LLC increased its position in Windtree Therapeutics by 559.5% in the 3rd quarter. Virtu Financial LLC now owns 100,808 shares of the company’s stock valued at $30,000 after acquiring an additional 85,522 shares during the period. Finally, Millennium Management LLC increased its position in Windtree Therapeutics by 411.1% in the 2nd quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock valued at $33,000 after acquiring an additional 64,232 shares during the period. 4.37% of the stock is currently owned by institutional investors and hedge funds.
Windtree Therapeutics Company Profile
Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension.
- Get a free copy of the StockNews.com research report on Windtree Therapeutics (WINT)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.